EGFR-directed treatment strategies were introduced in colorectal adenocarcinomas wild-type for NRAS and KRAS [12] and BRAF inhibitor treatment finds application in BRAF V600E mutated malignant melanomas [16]. The gene discussed is BRAF; the disease is colorectal adenocarcinoma.